Cynomolgus monkey (pivotal); supporting 4-week rat study
“The pivotal repeat-dose toxicity study is a 39 week study in Cynomolgus monkeys (study 070-087). A 4-week study in Sprague-Dawley rats was also conducted (study 54167).”
Cynomolgus monkey considered appropriate; adverse reactions similar to those in humans
“The Cynomolgus monkey was considered an appropriate species for safety testing of cetuximab. The similarity of adverse reactions seen in monkeys and humans supports this notion.”
Cynomolgus monkey (39-week pivotal); supporting 4-week Sprague-Dawley rat study
“The pivotal repeat-dose toxicity study is a 39 week study in Cynomolgus monkeys (study 070-087). A 4-week study in Sprague-Dawley rats was also conducted (study 54167).”
“Pregnant cynomolgus monkeys were administered cetuximab intravenously once weekly during the period of organogenesis (gestation day [GD] 20-48) at dose levels 0.4 to 4 times the recommended dose of ERBITUX based on body surface area (BSA).”